Compare Gilead Sciences, Inc. (GILD) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Under Armour Inc Class A — how do they compare? Gilead Sciences, Inc. trades at $133.32 (market cap $168.35B), while Under Armour Inc Class A trades at $5.32 (market cap $2.26B). The key difference: Gilead Sciences, Inc. is far larger — about 74.5× Under Armour Inc Class A's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| GILD | UAA | |
|---|---|---|
Market Cap | $168.35B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $8.14 |
52-Week Low | $110.56 | $4.17 |
Enterprise Value | $191.42B | $3.24B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Under Armour (UAA) trades at $5.86, down 4.09% today, reflecting ongoing challenges. The stock shows a bearish technical trend with support near $5.00. Fundamentally, the company reported a net loss of -$201.27M in 2025 with a negative net margin of -9.99%, though recent Q2 2026 earnings beat expectations. Revenue declined to $5.16B in 2025, and cash flow turned negative at -$361.87M. Analyst sentiment is mixed with a consensus price target of $6.67 but a majority hold rating.
The outlook remains cautious due to weak North American demand and margin pressures. Investment opportunities exist if the company executes its full-price strategy successfully, but risks include persistent revenue declines and high debt levels. The stock's proximity to its low price target of $5.00 underscores downside vulnerability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
